Semaglutide reduces weight, glucose levels, and CV risk in individuals with T2DM. Preclinical studies with a mechanical approach indicate that weight loss occurs due to the brain’s activation of GLP-1 receptors (GLP-1 Rs). The results presented in this context demonstrate that semaglutide altered food preferences, decreased food consumption, and caused weight loss without reducing energy expenditure. This evidence concerns the gene GCG and type 2 diabetes mellitus.